|
|
Marlborough House, Westminster Place York, North Yorkshire YO26 6RW UK phone:+44 (0)1904 520460 fax:+44 (0)1904 520461
|
|
| Symbol |
UTK |
| Exchange |
AMEX |
| Founded |
1997 |
| Employees |
|
|
|
| www.pharmalicensing.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Partnering Solutions for the Life Sciences |
 |
| Management |
| Mark McBride, Managing Director |
| |
|
|
|
|
|
|
|
| Keywords |
| pharmaceutical industry, biotech industry, life sciences, pharmalicensing, covering strategy |
|
|
|
| Description |
|
Pharmalicensing is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting in- and out-licensing activities, Pharmalicensing provides partnering services, business development reports and industry news. Pharmalicensing is actively utilized by over 190,000 industry professionals each month. |
 |
| Products / Services |
The www.Pharmalicensing.com service offers a unique combined Partner Search and on-line Profiling service for all areas of the lifesciences allowing users to identify and engage with prospective licensing, marketing and discovery/development partners around the world.
|
 |
| Technology / Differentiation |
| Pharmalicensing, alongside its sister company Medical Device Licensing, are divisions of UTEK Europe Ltd, which as been enabling global partenering activities across the lifesciences for the last twelve years. |
 |
| Market / Customers |
Pharmalicensing's customers are able to access over 190,000 visitors who come to the services every month, all of whom are looking to identify and engage with innovative partnering opportunities. To date, over 1,100 individuals across the top 20 pharma companies by R&D spend are registered and utilise the services as a key element of their partnering and business development activities
|
 |
| Funding |
| Pharmalicensing is a division of UTEK Europe Ltd, part of UTEK Corporation, listed on AMEX (UTK) |
 |
|
|
|
|
|
|